期刊文献+

替罗非班联合急诊PCI对急性心肌梗死疗效观察 被引量:3

下载PDF
导出
摘要 目的了解急性心肌梗死(AMI)行急诊经皮冠状动脉介入治疗(PCI)时,应用替罗非班改善冠状动脉血流和临床预后的疗效。方法所有确诊ST段抬高性心肌梗死(STEMI)并于发作6h内行急诊PCI手术患者80例,随机分为治疗组(A组)和控制组(B组)各40例,两组均给予急诊PCI术及氯吡格雷、阿司匹林、肝素和低分子肝素、他汀类、β受体阻滞剂等治疗,A组另给予替罗非班静脉内使用,观察两组在病变性质和术后即刻靶血管TIM/血流分级、术后心电图改变(ST段回落幅度)、术后30d内心脏不良事件(MACE)及出血事件发生率,并随访出院后MACE发生情况。结果A组PCI术后即刻靶血管TIMI血流分级明显高于B组,使用替罗非班治疗期间,A、B组出血事件及血小板减少症发生率比较,差异无统计学意义(P〉0.05),A组术后ST段回落幅度较B组明显、30d内MACE发生率明显低于B组,随访期间心血管不良事件发生率A组明显低于B组。结论在阿司匹林、氯吡格雷抗血小板治疗的基础上,ACS患者急诊PCI术中应用替罗非班比单纯PCI术及常规药物治疗,能进一步改善心肌灌注,从而改善预后。 Objective To evaluate the therapeutic effects of using tirofiban for improve coronary artery blood flow and the prognosis during treatment of emergency percataneous coronary interventional (PCI) for acute myocardial infarction (AMI). Methods All the 80 patients who were diagnosed ST segment elevation myocardial infarction (STEMI) and had emergency PCI, they were divided randomly into treating group( group A) and control group( group B) with 40 in each. Both of the two groups were given emergency PCI , clopidogrel , aspirin, heparin and low molecular heparin, statin drugs and β - receptor blocker . Tirofiban was administrated intravenously in addition. The progress of the disease, the targeted vessels TIMI blood flow grade,the postoperative ECG change( the ST segment's falling level) ,the major adverse cardiac events (MACE) ,the incidence rate of bleeding events and the follow - up MACE. Results The instant TIMI blood flow grade was in targeted vessels was significantly higher in group A than that in group B, there were no significant difference in bleeding events and the incidence rate of thrombopenia ( P 〉 0. 05 ), the failing level of ST segment in A group was higher than that in B group postoperatively, the incidence rate of MACE in group A was significantly lower than that in group B within 30d and during the follow up. Conclusions Based on the treatment of antiplatelet with aspirin and clopidogrel, patients of ACS can have better myocardial perfusion and a better prognosis when using tirofiban during emergency PCI.
出处 《浙江临床医学》 2009年第9期925-927,共3页 Zhejiang Clinical Medical Journal
关键词 急性冠状动脉综合征 替罗非班 经皮冠状动脉介入 Coronary syndrome Tirofiban Percataneous coronary interventional (PCI)
  • 相关文献

参考文献5

  • 1Bassand JP, Hamm CW. Guidelines for the diagnosis and treatment of non - ST - segment elevation acute coronary syndromes. Eur Heart J, 2007,28 : 1598 - 1660.
  • 2Kimmelstiel C, Badar J,Covic L, et al. Pharmaeodynamies and pharmacokineties of the platelet GP II b/III a inhibitor tirofiban in patients undergoing pereutaneous coronary intervention:implications for adjustment of tirofiban and clopidogrel dosage. Thromb Res,2005,55 -66.
  • 3Yang YJ,Zhao JL,You SJ,et al. Different effects of tirofiban and aspirin plus clopi - dogrel on myocardial no - reflow in a mini - swine model of acute myocardial infarction and reperfusion. Heart, 2006,92 (8) :1131.
  • 4刘鸿涛,曾秋棠,李裕舒,王祥,李大主,毛小波,毛奕.替罗非班对急性冠状动脉综合征患者介入术后炎症因子的影响[J].岭南心血管病杂志,2008,14(5):324-326. 被引量:3
  • 5Sorin J, Brener. The Benefits of Platetet Glycoprotein IIb/IIIa Receptor Inhibition During Primary Percutaneons Coronary Intervention for ST - Segment Elevation Myocardial Infarction, Journal of the American College of Cardiology ,2009,53 ( 18 ) : 1674 - 1676.

二级参考文献11

  • 1杨新春,徐立,王乐丰,葛永贵,王红石,丁枭伟,王文君,邹阳春,李惟铭,刘宇.国产替罗非班对急性心肌梗死患者急诊介入治疗术后冠状动脉血流和心肌灌注影响的研究[J].中国循环杂志,2006,21(1):4-7. 被引量:91
  • 2CHESEBRO J H, ZOLDHELYI P, FUSTER V. Plaque disruption and thrombosis in unstable angina pectoris [ J ]. Am J Cardiol, 1991, 68 (12): 9C-15C.
  • 3MACH F, SCHONBECK U, SUKHOVA G K, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells and macrophages: implication for CD40-CD40 ligand signaling in atherosclerosis [J]. Proc Natl Acad Sci USA, 1997, 94 (15) : 1931-1936.
  • 4HENN V, STEINBACH S, BUCHNER K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelet is temporally limited by eoexpresscd CD40[J]. Blood, 2001, 98 (4): 1047-1054.
  • 5GARLICHS C D, ESKAFI S, RAAZ D, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/ CD154 on platelets[J]. Heart, 2001, 86 (3): 649-655.
  • 6WILSON A M, RYAN M C, BOYLE A J. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathologen[J]. Int J Cardiol, 2006, 106 (3) : 291-297.
  • 7HEECHEN C, DIMMELER S, HAMM C W, et al. Soluble CD40 ligand in acute coronary syndromes [ J ]. N Engl J Med, 2003, 348 (12): 1104-1111.
  • 8KAI H, IKEDA H, YASUKAWA H, et al. Peripheral blood levels of matrix metalloproteases-2 and-9 are elevated in patients with acute coronary syndromes[Jl. J Am Coll Cardiol, 1998, 32 (2): 368-372.
  • 9NOMOTO K, OGUCHI S, WATANABE I, et al. Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1[J]. J Cardiol, 2003, 42 (5): 201-206.
  • 10ZENG B, PRASAN A, FUNG K C, et al. Elevated circulating levels of matrix metalloproteinase-9 and-2 in patients with symptomatic coronary artery disease[J]. Intern Med J, 2005, 35 (6): 331-335.

共引文献2

同被引文献36

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部